SABCS 2024 | Targeting DNA repair pathways for ADC-resistant HER2+ breast cancer
Jangsoon Lee, PhD, University of Hawai’i Cancer Center, Honolulu, HI, shares results from a recent translational study, which aimed to unravel the mechanisms of resistance to anti-HER2-based therapies, namely trastuzumab deruxtecan (T-DXd) and trastuzumab emtansine (T-DM1). Patients that were given these HER2 antibody-drug conjugates (ADC) demonstrated high levels of activity related to DNA repair and cell cycle pathways post-treatment. In-vitro and in-vivo pre-clinical studies also validated the DNA repair pathways as a therapeutic target for HER2+ breast cancer treatment. This interview took place at 2024 San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
